Novel anti-Helicobacter pylori therapies

Papers of special note have been highlighted as: • of interest

References

• 1 Alakkari A, Zullo A, O’Connor HJ. Helicobacter pylori and nonmalignant diseases. Helicobacter 16(Suppl. 1), 33–37 (2011).
  MedlineGoogle Scholar
• 2 Delahay RM, Rugge M. Pathogenesis of Helicobacter pylori infection. Helicobacter 17(Suppl. 1), 9–15 (2012).• Highlights the unique interaction between host and Helicobacter pylori.
  Medline CASGoogle Scholar
• 3 Campo SMA, Zullo A, Hassan C, Morini S. Antibiotic treatment strategies for Helicobacter pylori infection. Recent Pat. Antiinfect. Drug Discov. 2, 11–17 (2007).• Provides details about various antibiotics employed against H. pylori infection and their limitations.
  Medline CASGoogle Scholar
• 4 Malfertheiner P, Megraud F, O’Morain CA et al. Management of Helicobacter pylori infection – the Maastricht IV/Florence Consensus Report. Gut 61, 646–664 (2012).• The recent guidelines on indications for therapy, and management of H. pylori.
  Medline CASGoogle Scholar
• 5 O’Rourke J, Bode G. Chapter 6: Morphology and Ultrastructure. In: Helicobacter pylori: Physiology and Genetics Mobley HLT, Mendz GL, Hazell SL (Eds). ASM Press, Washington, DC, USA (2001).
  Google Scholar
• 6 Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 321(8336), 1273–1275 (1983).
  Google Scholar
• 7 Goodwin CS, Armstrong JA, Chilvers T et al. Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., respectively. Int. J. Syst. Bacteriol. 39(4), 397–405 (1989).
  Google Scholar
• 8 Ohno T, Vallström A, Rugge M et al. Effects of blood group antigen-binding adhesin expression during Helicobacter pylori infection of mongolian gerbils. J. Infect. Dis. 203(5), 726–735 (2011).
  Medline CASGoogle Scholar
• 9 Papamichael K, Mantzaris GJ. Pathogenesis of Helicobacter pylori infection: colonization, virulence factors of the bacterium and immune and non-immune host response. Hospital Chronicals 7(1), 32–37 (2012).
  Google Scholar
• 10 Matsuda K, Yamauchi K, Matsumoto T, Sano K, Yamaoka Y, Ota H. Quantitative analysis of the effect of Helicobacter pylori on the expressions of SOX2, CDX2, MUC2, MUC5AC, MUC6, TFF1, TFF2, and TFF3 mRNAs in human gastric carcinoma cells. Scand. J. Gastroenterol. 43(1), 25–33 (2008).
  Medline CASGoogle Scholar
• 11 Amieva MR, El-Omar EM. Host–bacterial interactions in Helicobacter pylori infection. Gastroenterology 134(1), 306–323 (2008).
  Medline CASGoogle Scholar
• 12 De Francesco V, Ierardi E, Hassan C, Zullo A. Helicobacter pylori therapy: Present and future. World J. Gastrointest. Pharmacol. Ther. 3(4), 68–73 (2012).• Provides an excellent insight into anti-H. pylori therapy and its present status.
  MedlineGoogle Scholar
• 13 Fiorini G, Zullo A, Gatta L et al. Newer agents for Helicobacter pylori eradication. Clin. Exp. Gastroenterol. 5, 109–112 (2012).• An update on newer agents for H. pylori clearance.
  Medline CASGoogle Scholar
• 14 De Francesco V, Giorgio F, Hassan C et al. Worldwide H. pylori antibiotic resistance: a systemic review. J. Gastrointestin. Liver Dis. 19(4), 409–414 (2010).
  MedlineGoogle Scholar
• 15 Sancheza JE, Saenza NG, Rinconb MR, Martina IT, Sancheza EG, Martineza MJ. Susceptibility of Helicobacter pylori to mupirocin, oxazolidinones, quinupristin/dalfopristin and new quinolones. J. Antimicrob. Chemother. 46, 283–285 (2000).
  MedlineGoogle Scholar
• 16 Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 7(4), 201–211 (2014).
  Google Scholar
• 17 Shin JM, Homerin M, Domagala F, Ficheux H, Sachs G. Characterization of the inhibitory activity of tenatoprazole on the gastric H+, K+ -ATPase in vitro and in vivo. Biochem. Pharmacol. 71(6), 837–849 (2006).
  Medline CASGoogle Scholar
• 18 Metz DC, Vakily M, Dixit T, Mulford D. Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Aliment. Pharmacol. Ther. 29(9), 928–937 (2009).
  Medline CASGoogle Scholar
• 19 Wang L, Zhou L, Lin S, Hu H, Xia J. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J. Clin. Gastroenterol. 45(4), 322–329 (2011).
  Medline CASGoogle Scholar
• 20 Pai V, Pai N. Randomized, double-blind, comparative study of dexrabeprazole 10 mg versus rabeprazole 20 mg in the treatment of gastroesophageal reflux disease. World J. Gastroenterol. 14, 4100–4102 (2007).
  Google Scholar
• 21 Santarus Inc.: US0092658 (2009).
  Google Scholar
• 22 Accumed LLC, Q-Pharma LLC: US0057125 (2008).
  Google Scholar
• 23 Chuah S-K, Tsay FW, Hsu P-I, Wu D-C. A new look at anti-Helicobacter pylori therapy. World J. Gastroenterol. 17(35), 3971–3975 (2011).• Provides the recent perspective on anti-H. pylori treatment.
  Medline CASGoogle Scholar
• 24 Graham DY. Efficient identification and evaluation of effective Helicobacter pylori therapies. Clin. Gastroenterol. Hepatol. 7, 145–148 (2009).
  MedlineGoogle Scholar
• 25 Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 133, 985–1001 (2007).
  Medline CASGoogle Scholar
• 26 Thirumurthi S, Graham DY. Helicobacter pylori infection in India from a western perspective. Ind. J. Med. Res. 136, 549–562 (2012).
  Medline CASGoogle Scholar
• 27 Zullo A, Hassan C, D’Ercole C, D Francesco V, Vaira D. Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication? Aliment. Pharmacol. Ther. 31(11), 1248–1249 (2010).
  Medline CASGoogle Scholar
• 28 Eisai R&D Management Co. Ltd: US0110727 (2009).
  Google Scholar
• 29 Flamel Technologies SA: US0068291 (2010).
  Google Scholar
• 30 AstraZeneca AB: US0095853 (2008).
  Google Scholar
• 31 Apta Pharma Inc.: US0280175 (2009).
  Google Scholar
• 32 Intellipharmaceuticals Corp.: US0129442 (2010).
  Google Scholar
• 33 The Curators of the University of Missouri: US8247440 (2012).
  Google Scholar
• 34 Cadila Healthcare Ltd.: US0216617 (2013).
  Google Scholar
• 35 Dermatrends Inc.: US0287502 (2008).
  Google Scholar
• 36 Yun SP, Son SG, Ok CS et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver 6(4), 452–456 (2012).
  Medline CASGoogle Scholar
• 37 Strides Arcolab Ltd: WO0044093 (2010).
  Google Scholar
• 38 Basu PP, Rayapudi K, Pacana T, Shah NJ, Krishnaswamy N, Flynn M. A randomized study comparing levofloxacin, omeprazole, nitazoxanide, and doxycycline versus triple therapy for the eradication of Helicobacter pylori. Am. J. Gastroenterol. 106(11), 1970–1975 (2011).
  Medline CASGoogle Scholar
• 39 Monash University: US0086911 (2011).
  Google Scholar
• 40 Fakheri H, Bari Z, Sardarian H. A modified bismuth-containing quadruple therapy including a short course of furazolidone for Helicobacter pylori eradication after sequential therapy failure. Helicobacter 17(4), 264–268 (2012).
  Medline CASGoogle Scholar
• 41 Hsu P-I, Chen W-C, Tsay F-W et al. On behalf of the Taiwan Acid-Related Disease (TARD) Study Group. Ten-day quadruple therapy comprising proton-pump inhibitor, bismuth, tetracycline, and levofloxacin achieves a high eradication rate for Helicobacter pylori infection after failure of sequential therapy. Helicobacter 19(1), 74–79 (2014).
  Medline CASGoogle Scholar
• 42 Nycomed GMBH/Takeda Pharmaceutical Company Ltd: US0189590 (2007).
  Google Scholar
• 43 Cipla Ltd: US0161579 (2008).
  Google Scholar
• 44 Takeda Pharmaceutical Company Ltd: US0028476 (2011).
  Google Scholar
• 45 Lek Pharmaceuticals DD: US0046319 (2012).
  Google Scholar
• 46 Nycomed GMBH: US0022779 (2010).
  Google Scholar
• 47 Alevium Pharmaceuticals, Inc.: US0317689 (2010).
  Google Scholar
• 48 Allergan, Inc.: US0060621 (2007).
  Google Scholar
• 49 Altana pPharma AG/Nycomed GMBH: US0244115 (2007).
  Google Scholar
• 50 Sidem Pharma: US7402593 (2008).
  Google Scholar
• 51 Chongqing University of Technology: CN103102302 A (2013).
  Google Scholar
• 52 Chongqing University of Technology: CN103113295 (2013).
  Google Scholar
• 53 Achaogen Inc.: WO1031745 (2011).
  Google Scholar
• 54 Yang JC, Lee PI, Hsueh PR. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998–2007. Eur. J. Clin. Microbiol. Infect. Dis. 29(11), 1369–1375 (2010).
  Medline CASGoogle Scholar
• 55 Taigen Biotechnology Co. Ltd: US8211909 (2012).
  Google Scholar
• 56 Lahner E, Persechino S, Annibale B. Micronutrients (other than iron) and Helicobacter pylori infection: a systemic review. Helicobacter 17(1), 1–15 (2012).
  Medline CASGoogle Scholar
• 57 Yale University, NIH: US0150861 (2010).
  Google Scholar
• 58 Souls Disinfectant Co Ltd: CN102088984 (2012).
  Google Scholar
• 59 Vitor JMB, Vale FF. Alternative therapies for Helicobacter pylori: probiotics and phytomedicine. FEMS Immunol. Med. Microbiol. 63, 153–164 (2011).
  Medline CASGoogle Scholar
• 60 Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment. Pharmacol. Ther. 23, 1077–1086 (2006).
  Medline CASGoogle Scholar
• 61 Dikovskiy AV, Dorozhko OV: US0028914 (2012).
  Google Scholar
• 62 De Bortoli N, Leonardi G, Ciancia E et al. Helicobacter pylori eradication: a randomized, prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am. J. Gastroenterol. 102, 951–956 (2007).
  Medline CASGoogle Scholar
• 63 Auckland Uniservices Ltd: US0214618 (2008).
  Google Scholar
• 64 Figura N, Marcolongo R, Cavallo G et al. Polysorbate 80 and Helicobacter pylori: a microbiological and ultrastructural study. BMC Microbiol. 12, 217 (2012).
  Medline CASGoogle Scholar
• 65 Over SRL: US0217641 (2013).
  Google Scholar
• 66 Goswami S, Bhakuni RS, Chinniah A, Pal A, Kar SK, Das PK. Anti-Helicobacter pylori potential of artemisinin and its derivatives. Antimicrob. Agents Chemother. 56(9), 4594–4607 (2012).
  Medline CASGoogle Scholar
• 67 Marash M, Kluev E: WO5048912 (2005).
  Google Scholar
• 68 Hagen SJ, Ohtani M, Zhou J-R et al. Inflammation and foveolar hyperplasia are reduced by supplemental dietary glutamine during Helicobacter pylori infection in mice. J. Nutr. 139(5), 912–918 (2009).
  Medline CASGoogle Scholar
• 69 Nishida H, Hasuoka A, Arikawa Y et al. Discovery, synthesis, and biological evaluation of novel pyrrole derivatives as highly selective potassium-competitive acid blockers. Bioorg. Med. Chem. 20, 3925–3938 (2012).• A detailed review on the reversible acid pump antagonists.
  Medline CASGoogle Scholar
• 70 Lee J-S, Cho J-Y, Song H, Kim E-H, Hahm K-B. Revaprazan, a novel acid pump antagonist, exerts anti-inflammatory action against Helicobacter pylori-induced COX-2 expression by inactivating Akt signaling. J. Clin. Biochem. Nutr. 51(2), 77–83 (2012).
  Medline CASGoogle Scholar
• 71 Jung JW, Kang HR, Kwon JW et al. The potential inhibitory effect of revaprazan, an acid pump antagonist, on anticoagulation with warfarin. Tohoku J. Exp. Med. 224(4), 293–300 (2011).
  Medline CASGoogle Scholar
• 72 Yuhan Corporation: WO2108631 (2012).
  Google Scholar
• 73 Inatomi N, Matsukawa J. A new gastric acid suppressant: potassium-competitive acid blocker, TAK-438. Med. Sci. Digest 38(12), 546–550 (2012).
  Google Scholar
• 74 Takeda Pharmaceutical Company: WO8108380 (2008).
  Google Scholar
• 75 Raqualia Pharma Inc.: US0048532 (2010).
  Google Scholar
• 76 Raqualia Pharma Inc.: US0214519 (2008).
  Google Scholar
• 77 Innovative Pharmacology Research OOO: US0329804 (2013).
  Google Scholar
• 78 Scarpignato C, Hunt RH. Proton pump inhibitors: the beginning of the end or the end of the beginning? Curr. Opin. Pharmacol. 8(6), 677–684 (2008).
  Medline CASGoogle Scholar
• 79 Nitromed Inc.: US0179150 (2007).
  Google Scholar
• 80 Univ Boston: WO8019292 (2008).
  Google Scholar
• 81 Wockhardt Research Centre: WO1101710 (2011).
  Google Scholar
• 82 Shionogi and Co.: US0116493 (2004).
  Google Scholar
• 83 Solomon LR, Cheesbrough JS, Ebah L et al. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis. Am. J. Kidney Dis. 55(6), 1060–1068 (2010).
  Medline CASGoogle Scholar
• 84 Polaschegg H-D: US0085469 (2013).
  Google Scholar
• 85 Nabriva Therapeutics AG: US7790749 (2010).
  Google Scholar
• 86 Shang R, Wang J, Guo W, Liang J. Efficient antibacterial agents: a review of the synthesis, biological evaluation and mechanism of pleuromutilin derivatives. Curr. Top. Med. Chem. 13(24), 3013–3025 (2013).
  Medline CASGoogle Scholar
• 87 Makobongo MO, Einck L, Peek RM Jr, Merrell DS. In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori. PLoS ONE 8(7), e68917 (2013).
  Medline CASGoogle Scholar
• 88 Sequella Inc.: US7884097 (2011).
  Google Scholar
• 89 Rothstein DM, Mullin S, Sirokman K et al. Rifalazil and derivative compounds show potent efficacy in a mouse model of H. pylori colonization. J. Antibiot. (Tokyo) 61(8), 485–488 (2008).
  Medline CASGoogle Scholar
• 90 Cabana BE, Magnant GP, Michaelis AF, Sayda CB. US0046281 (2012).
  Google Scholar
• 91 Activbiotics Pharma, LLC: WO0005836 (2010).
  Google Scholar
• 92 Activbiotics Pharma, LLC: US7820652 (2010).
  Google Scholar
• 93 Arigen Pharmaceuticals Inc.: US0173944 (2010).
  Google Scholar
• 94 Arigen Pharmaceuticals Inc.: US0143438 (2009).
  Google Scholar
• 95 Asadipour A, Edraki N, Nakhjiri M et al. Anti-Helicobacter pylori activity and structure-activity relationship study of 2-alkylthio-5-(nitroaryl)-1,3,4-thiadiazole derivatives. Iran. J. Pharm. Res. 12(3), 281–287 (2013).
  Medline CASGoogle Scholar
• 96 Arigen Pharmaceuticals Inc.: US0041030 (2012).
  Google Scholar
• 97 Chemeq Ltd: US7629002 (2009).
  Google Scholar
• 98 Aoki W, Ueda M. Characterization of antimicrobial peptides toward the development of novel antibiotics. Pharmaceuticals (Basel) 6(8), 1055–1081 (2013).
  Medline CASGoogle Scholar
• 99 Makobongo MO, Gancz H, Carpenter BM, McDaniel DP, Merrell S. The oligo-acyl lysyl antimicrobial peptide C12K-2β12 exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob. Agents Chemother. 56(1), 378–390 (2012).
  Medline CASGoogle Scholar
• 100 Okuda M, Yamamoto N, Fukuda N et al. Effect of ecabet sodium treatment on urea breath test and stool antigen tests in volunteers with Helicobacter pylori infection. J. Gastroenterol. Hepatol. 27(Suppl. 3), 100–102 (2012).
  Medline CASGoogle Scholar
• 101 Tanabe Seiyaku Co.: WO3028716 (2003).
  Google Scholar
• 102 Wang Y, Tang N, Meng L et al. Safety and tolerability of bismuthyl Ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects. Clin. Drug Invest. 32(4), 247–252 (2012).
  Medline CASGoogle Scholar
• 103 National University of Ireland, Dublin: WO3004669 (2013).
  Google Scholar
• 104 National Tsing Hua University: US8175860 (2012).
  Google Scholar
• 105 Council Scient. Ind. RES: WO8015524 (2008).
  Google Scholar
• 106 Strugatsky D, McNulty R, Munson K et al. Structure of the proton-gated urea channel from the gastric pathogen Helicobacter pylori. Nature 493, 255–258 (2013).
  Medline CASGoogle Scholar
• 107 Cheng C-S, Jia K-F, Chen T, Chang S-Y, Lin M-S, Yin H-S. Experimentally validated novel inhibitors of Helicobacter pylori phosphopantetheine adenylyltransferase discovered by virtual high-throughput screening. PLoS ONE 8(9), e74271 (2013).
  Medline CASGoogle Scholar
• 108 Rivera-Ordaz A, Bracher S, Sarrach S et al. The sodium/proline transporter PutP of Helicobacter pylori. PLoS ONE 8(12), e83576 (2013).
  MedlineGoogle Scholar
• 109 Zou Q-H, Wei W. Phage. therapy: promising for H. pylori infection. Clin. Microbiol. (Tokyo) 2, 112 (2013).
  Google Scholar
• 110 Universidad de Zaragoza: US0317862 (2010).
  Google Scholar
• 111 Warren CA, van Opstal E, Ballard TC et al. Amixicile, a novel inhibitor of pyruvate: ferredoxin oxidoreductase, shows efficacy against Clostridium difficile in a mouse infection model. Antimicrob. Agents Chemother. 56(8), 4103–4111 (2012).
  Medline CASGoogle Scholar
• 112 Takeda Pharmaceutical Company Ltd: US7671174 (2010).
  Google Scholar
• 113 Takeda Pharmaceutical Company Ltd: US0227501 (2009).
  Google Scholar
• 114 Giudice GD, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev. Vaccines 8(8), 1037–1049 (2009).
  MedlineGoogle Scholar
• 115 Life Spring Immuno Science Corp.: US0011437 (2013).
  Google Scholar
• 116 Summerton NA, Welch RW, Bondoc L et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 28, 1404–1411 (2010).
  Medline CASGoogle Scholar
• 117 Helicure AB: US8025880 (2011).
  Google Scholar
• 118 Caselli M, Cassol F, Calo G, Holton J, Zuliani G, Gasbarrini A. Actual concept of 'probiotics': is it more functional to science or business? World J. Gastroenterol. 19(10), 1527–1540 (2013).
  MedlineGoogle Scholar
• 119 Bioengineering Institute of Military Medical Sciences: CN101863964 (2013).
  Google Scholar
• 120 Chongqing Kang Wei Biotechnology Co. Ltd: IP252901 (2012).
  Google Scholar
• 121 Hongying F, Xianbo W, Fang Y, Yang B, Beiguo L. Oral immunization with recombinant Lactobacillus acidophilus expressing the adhesin Hp0410 of Helicobacter pylori induces mucosal and systemic immune responses. Clin. Vaccine Immunol. 21, 126–132 (2014).
  MedlineGoogle Scholar
• 122 Novartis Vaccines and Diagnostics Inc.: US7901907 (2011).
  Google Scholar
• 123 Rican Ltd: IP240197 (2010).
  Google Scholar
• 124 Inoue K, Shiota S, Yamada K et al. A evaluation of a new tumor necrosis factor-alpha-inducing membrane protein of Helicobacter pylori as a prophylactic vaccine antigen. Helicobacter 14, 135–143 (2009).
  Medline CASGoogle Scholar
• 125 Kim SJ, Lee JY, Jun DY et al. Oral administration of Lactococcus lactis expressing Helicobacter pylori Cag7-ct383 protein induces systemic anti-Cag7 immune response in mice. FEMS Immunol. Med. Microbiol. 57, 257–268 (2009).
  Medline CASGoogle Scholar
• 126 Malfertheiner P, Schultze V, Rosenkranz B et al. Safety and immunogenicity of an intramuscular Helicobacter pylori vaccine in noninfected volunteers: a Phase I study. Gastroenterol. 135, 787–895 (2008).
  Medline CASGoogle Scholar
• 127 China Pharmaceutical University: CN102178941 (2013).
  Google Scholar
• 128 AstraZeneca AB: US6838089 (2005).
  Google Scholar
• 129 Amaral MRRL, Goncalves L, Almeida A. Evaluation of a new vaccine based on pDNA and recombinant protein against Helicobacter pylori. www.hdl.handle.net/10362/8520
  Google Scholar
• 130 Figueiredo L, Calado CCR, Almeida AJ, Goncalves LMD. Protein and DNA nanoparticulate multiantigenic vaccines against H. pylori: in vivo evaluation. Presented at: IEEE 2nd Portuguese Meeting in English. Coimbra, Portugal 23–25 February 2012.
  Google Scholar
• 131 Talebkhan Y, Bababeik M, Esmaeili M et al. Helicobacter pylori bacterial ghost containing recombinant Omp18 as a putative vaccine. J. Microbiol. Methods 82(3), 334–337 (2010).
  Medline CASGoogle Scholar
• 132 Medical and Pharmaceutical Industry Technology and Development Center: US8470379 (2013).
  Google Scholar
• 133 Ceramoptec Industries Inc.: US0245198 (2011).
  Google Scholar
• 134 Arjuna Natural Extracts, Ltd: US0207863 (2012).
  Google Scholar
• 135 Arjuna Natural Extracts, Ltd.: US7883728 (2008).
  Google Scholar
• 136 Sologran Ltd: US0039816 (2011).
  Google Scholar
• 137 Messing J, Thole C, Niehues M et al. Antiadhesive properties of Abelmoschus esculentus (Okra) immature fruit extract against Helicobacter pylori adhesion. PLoS ONE 9(1), e84836 (2014).
  MedlineGoogle Scholar
• 138 Yamaguchi K, Kono T: US8241683 (2012).
  Google Scholar
• 139 Martini S, D‘Addario C, Colacevich A et al. Antimicrobial activity against Helicobacter pylori strains and antioxidant properties of blackberry leale (Rubus ulmifolius) and isolated components. Int. J. Antimicrob. Agents 34, 50–59 (2009).
  Medline CASGoogle Scholar
• 140 Rasmussen LT, de Labio RW, Gatii LL et al. Helicobacter pylori detection in gastric biopsies, saliva and dental plaque of Brazilian dyspeptic patients. Mem. Inst. Oswaldo Cruz 105(3) 326–330 (2010).
  MedlineGoogle Scholar